Arshdeep Tindni, MD
Nephrology · Cincinnati, OHNPI 1023138401
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,615 of the $40,771 with a category attached, or 77.5%. 34 manufacturers reported payments, led by Bayer at 36.7% of the total. 2025 is the largest year on record at $14,815, more than ten times the $851 reported in 2019. Among nephrology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 277 payments — averaging $147.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$15K
- Akebia Therapeutics Inc$15K
- Calliditas Therapeutics US Inc.$6K
- AstraZeneca$912
- Mallinckrodt Hospital Products Inc.$455
- Vifor Pharma, Inc.$452
- plus $3K from 28 others
What the payments were for
- Speaking & faculty fees$31,61578%
- Travel & lodging$2,2025%
- Food & beverage$6,74817%
- Education$2051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 30 | $14,973 |
| Akebia Therapeutics Inc | 31 | $14,628 |
| Calliditas Therapeutics US Inc. | 21 | $6,240 |
| AstraZeneca(2 entities) | 32 | $912 |
| Mallinckrodt Hospital Products Inc. | 8 | $455 |
| Vifor Pharma, Inc. | 23 | $452 |
| Fresenius USA Marketing, Inc. | 13 | $385 |
| Amgen(2 entities) | 20 | $380 |
| Mallinckrodt Enterprises LLC | 6 | $330 |
| GSK | 12 | $308 |
| Novartis | 12 | $266 |
| OPKO Pharmaceuticals, LLC | 14 | $253 |
| Otsuka America Pharmaceutical, Inc. | 8 | $223 |
| Ardelyx, Inc. | 3 | $149 |
| Aurinia Pharma U.S., Inc. | 4 | $95 |
| Nxstage Medical, Inc. | 2 | $88 |
| Boehringer Ingelheim | 4 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $68 |
| Travere Therapeutics, Inc. | 7 | $61 |
| Outset Medical Inc | 1 | $59 |
| Ultragenyx Pharmaceutical Inc. | 3 | $52 |
| Sunovion Pharmaceuticals Inc. | 4 | $43 |
| Alnylam Pharmaceuticals Inc. | 2 | $40 |
| Daiichi Sankyo Inc. | 3 | $38 |
| Pharmacosmos Therapeutics Inc. | 2 | $30 |
| Qorumpartners | 1 | $26 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Renalytix AI, Inc. | 1 | $21 |
| Merck | 1 | $19 |
| Bard Peripheral Vascular, Inc. | 1 | $18 |
| Apellis Pharmaceuticals, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $14 |
| Gilead | 1 | $14 |
| CMP Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,771 in reported general payments places this provider in the 90th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 363 | $400,987 |
| FarxigaDapagliflozin Propanediol | 117 | $98,280 |
| LokelmaSodium Zirconium Cyclosilicate | 53 | $61,635 |
| VelphoroSucroferric Oxyhydroxide | 36 | $60,522 |
| KerendiaFinerenone | 42 | $46,692 |
| VeltassaPatiromer Calcium Sorbitex | 30 | $28,275 |
| AuryxiaFerric Citrate | 12 | $26,063 |
| ClinisolParenteral Amino Acid 15% No.5 | 105 | $14,082 |
| JanuviaSitagliptin Phosphate | 22 | $13,917 |
| Torsemide | 430 | $10,823 |
| EntrestoSacubitril/Valsartan | 11 | $10,120 |
| EliquisApixaban | 18 | $9,840 |
| Midodrine Hcl | 46 | $8,930 |
| Spironolactone | 658 | $8,584 |
| Eplerenone | 78 | $8,292 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $81 | $400,987363 claims |
| AstraZenecaFarxiga, Lokelma | $912 | $159,915170 claims |
| Fresenius USA Marketing, Inc.Velphoro | $385 | $60,52236 claims |
| BayerKerendia | $14,973 | $46,69242 claims |
| Akebia Therapeutics IncAuryxia | $14,628 | $26,06312 claims |
| MerckJanuvia | $19 | $13,91722 claims |
| NovartisEntresto | $266 | $10,12011 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $22 | $6,834258 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 450 nephrology providers in Ohio.
Other nephrology in Cincinnati
- Amit GovilCincinnati$298K
- Prabir Roy ChaudhuryCincinnati$205K
- Charuhas ThakarCincinnati$107K
- Chebel KhalilCincinnati$72K
- Joseph KremerCincinnati$29K
- Tahir SajjadCincinnati$20K
- Silvi ShahCincinnati$14K
- Prakash GudsoorkarCincinnati$10K
- Ahmad AnjakCincinnati$9K
- Karl PembaurCincinnati$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.